CoQmax Omega Disease Interactions
There are 2 disease interactions with CoQmax Omega (omega-3 polyunsaturated fatty acids / ubiquinone).
Omega-3 fatty acids (applies to CoQmax Omega) arrhythmias
Moderate Potential Hazard, Moderate plausibility.
Cases of recurrent atrial fibrillation (AF) or flutter have been reported with the use of omega-3 fatty acids in patients with a symptomatic paroxysmal AF or persistent AF. This condition is more apparent within the first 2 to 3 months after the initiation of therapy. Therapy with these agents should be administered cautiously in patients with cardiac conduction disorders.
Omega-3 fatty acids (applies to CoQmax Omega) liver disease
Moderate Potential Hazard, Moderate plausibility.
Increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels have been observed in patients receiving omega-3 fatty acids. Therapy with omega-3 fatty acid preparations should be administered cautiously in patients with hepatic impairment. Serum liver enzyme levels should be monitored periodically.
Switch to professional interaction data
CoQmax Omega drug interactions
There are 76 drug interactions with CoQmax Omega (omega-3 polyunsaturated fatty acids / ubiquinone).
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.